Combined Hepatocellular-cholangiocarcinoma

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma [Phase 2]

  This is a Phase II clinical trial evaluating a combination of tremelimumab, durvalumab, gemcitabine, and cisplatin for locally advanced unre…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer [Phase 2]

  This Phase 2 trial evaluates whether chemotherapy with atezolizumab is superior to chemotherapy with bevacizumab and atezolizumab in patient…

• CLINICAL_TRIALS research · 2025-11-24
  Clinical Trial Update: Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma [Phase 2]

  Phase II trial update for Cadonilimab plus Capecitabine as adjuvant therapy for combined hepatocellular-cholangiocarcinoma and intrahepatic …

• CLINICAL_TRIALS research · 2025-08-05
  Clinical Trial Update: A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

  A French multicenter observational retrospective study aimed at characterizing rare primary liver cancers, currently recruiting, including s…

• CLINICAL_TRIALS research · 2025-02-27
  Clinical Trial Update: Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

  Clinical trial update examining novel subtypes and multimodal treatment strategies for unresectable combined hepatocellular-cholangiocarcino…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.